Related news from
Wed, 24 Apr 2024 20:05:00 +0000	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a u
Tue, 23 Apr 2024 16:12:00 +0000	Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
Mon, 22 Apr 2024 12:00:00 +0000	Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etio
Wed, 17 Apr 2024 16:00:09 +0000	Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Tue, 16 Apr 2024 15:34:00 +0000	Corcept (CORT) Completes Enrollment in Phase II ALS Study The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
Mon, 15 Apr 2024 12:00:00 +0000	Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patien
Tue, 09 Apr 2024 15:09:00 +0000	Corcept (CORT) Completes Enrollment in Ovarian Cancer Study The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
Mon, 08 Apr 2024 12:00:00 +0000	Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in ROSELLA, a pivotal Phase 3 trial of its proprietary selective cortisol modulator relacorilant combined with nab-paclitaxel in patients with
Mon, 01 Apr 2024 12:00:00 +0000	Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing’s syndrome (hypercortisolis
Fri, 29 Mar 2024 15:30:29 +0000	Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report? Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 29 Mar 2024 10:37:02 +0000	Investing in Corcept Therapeutics (NASDAQ:CORT) five years ago would have delivered you a 114% gain While Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders are probably generally happy, the stock hasn't had...
Wed, 27 Mar 2024 15:30:21 +0000	Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mon, 25 Mar 2024 14:20:00 +0000	Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry? Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Fri, 22 Mar 2024 15:30:48 +0000	Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report? United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sat, 17 Feb 2024 13:18:13 +0000	Corcept Therapeutics Full Year 2023 Earnings: Beats Expectations Corcept Therapeutics ( NASDAQ:CORT ) Full Year 2023 Results Key Financial Results Revenue: US$482.4m (up 20% from FY...
Fri, 16 Feb 2024 18:33:00 +0000	Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
Fri, 16 Feb 2024 14:04:34 +0000	Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript February 15, 2024 Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.28, expectations were $0.25. Corcept Therapeutics Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Corcept […]
Fri, 16 Feb 2024 13:57:31 +0000	Q4 2023 Corcept Therapeutics Inc Earnings Call Q4 2023 Corcept Therapeutics Inc Earnings Call
Thu, 15 Feb 2024 21:44:57 +0000	Corcept Therapeutics Inc Reports Significant Revenue Growth and Net Income Increase in Q4 and ... Continued Commercial Success and Advancements in Clinical Programs Mark a Strong Year for the Biopharmaceutical Company
Thu, 15 Feb 2024 21:07:00 +0000	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2023. Financial Results Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2